Mounjaro vs Liraglutide: Cost, Access, and Which Works Better for Women

What Are These Two Drugs, and Why Does the Comparison Matter for Women?

Mounjaro and liraglutide sit in the same GLP-1 class but work differently and cost differently. Understanding those differences matters especially if you are managing weight alongside a hormone-driven condition such as PCOS, perimenopause, or thyroid disease.

Liraglutide is a GLP-1 receptor agonist that has been on the US market since 2010 (Victoza, for type 2 diabetes) and 2014 (Saxenda, for obesity). It mimics the gut hormone GLP-1, slowing gastric emptying, reducing appetite, and improving insulin secretion.

Mounjaro (tirzepatide) does all of that and adds a second action: it also activates the GIP (glucose-dependent insulinotropic polypeptide) receptor. That dual agonism appears to be why it outperforms older single-receptor GLP-1 drugs on weight and glucose outcomes. The FDA approved Mounjaro for type 2 diabetes in May 2022, and Zepbound (same molecule, obesity indication) in November 2023.

No published randomized trial has placed tirzepatide and liraglutide head-to-head in a single study. The comparison below synthesizes evidence from each drug's own trials, which enrolled different populations. Read those trial numbers with that caveat in mind.

How Much Weight Do They Each Produce?

Liraglutide: The SCALE Obesity Data

In the SCALE Obesity trial (NEJM 2015), adults with a BMI of 30 or greater (or BMI <30 with a weight-related comorbidity) who received liraglutide 3.0 mg daily lost a mean of 8.0% of body weight at 56 weeks compared with 2.6% on placebo. Roughly 63% of liraglutide participants lost at least 5% of body weight.

That is meaningful. Losing 5-10% of body weight produces measurable improvements in insulin sensitivity, menstrual regularity in PCOS, blood pressure, and sleep apnea. For women who need modest, steady weight reduction without the cost or supply constraints of newer agents, liraglutide delivers a clinically relevant result.

Mounjaro: What SURPASS-2 and SURMOUNT-1 Show

In SURPASS-2 (NEJM 2021), tirzepatide at 10 mg and 15 mg weekly reduced A1C by 2.01% and 2.30% respectively, and produced weight loss of 9.3 kg (10 mg) and 11.2 kg (15 mg) in adults with type 2 diabetes, all significantly greater than semaglutide 1 mg. Tirzepatide was not compared to liraglutide in that trial, but the placebo-subtracted weight loss in SURPASS-2 already exceeds liraglutide's absolute figures from SCALE.

In the obesity-specific SURMOUNT-1 trial, participants without diabetes lost up to 20.9% of body weight on tirzepatide 15 mg at 72 weeks compared with 3.1% on placebo. That figure is roughly 2.5 times the weight loss seen with liraglutide in SCALE at a shorter timeframe.

The Honest Caveat

These trials enrolled different populations, used different durations, and ran in different eras of background care. A direct comparison is an extrapolation, not a fact. Women who did well on liraglutide in trials may have characteristics that differ from those enrolled in SURMOUNT-1. Women were approximately 67% of SURMOUNT-1 participants, which is better female representation than many metabolic trials, though subgroup data by sex have not been fully published.

Cost and Access: The Real-World Numbers

List Prices in 2024

Cost is not abstract for most women. Here is where the two drugs stand in the United States:

• Mounjaro (tirzepatide): List price approximately $1,069 per month for the 2.5 mg or 5 mg pen. Higher doses cost slightly more. Eli Lilly's Savings Card can reduce out-of-pocket costs to as low as $25/month for commercially insured patients who qualify.
• Saxenda (liraglutide brand): List price approximately $1,349 per month for the obesity indication (3.0 mg). Novo Nordisk savings programs exist but vary.
• Generic liraglutide (Victoza formulation): Generic versions of Victoza (1.2 mg and 1.8 mg, diabetes indication) became available in the US in 2024, with prices that can reach as low as $200-400/month depending on pharmacy and negotiated discount. Note that generic availability targets the diabetes dose, not the 3.0 mg obesity dose, so access depends on your indication.

Insurance Coverage

Mounjaro coverage for diabetes is broad among commercial plans. Coverage for Zepbound (tirzepatide for obesity) is improving but still variable. Many Medicare Part D plans excluded obesity drugs until the CMMI Obesity Drugs Pilot program expanded access in 2024.

Liraglutide at the 1.8 mg diabetes dose is now frequently covered as a preferred tier agent now that generics exist. Saxenda (3.0 mg, obesity indication) coverage has historically been patchy; generic competition may push down costs but generic availability at the obesity dose is not yet widespread as of early 2025.

Telehealth Access and Compounded Versions

Several telehealth platforms prescribe compounded tirzepatide and compounded semaglutide during shortage periods. The FDA allowed compounded tirzepatide while Mounjaro and Zepbound were on the shortage list. That status changed in late 2024 when the FDA removed tirzepatide from the drug shortage database, triggering a phase-out of compounded versions. If you are currently using a compounded tirzepatide, your prescriber should have discussed the transition timeline with you.

Compounded liraglutide is less commonly prescribed but has been available from 503B outsourcing facilities.

Dosing, Administration, and the Convenience Factor

Liraglutide: Daily Shots

Liraglutide requires a daily subcutaneous injection. You start at 0.6 mg for one week, increase to 1.2 mg, and titrate up to 3.0 mg over four to five weeks. The daily injection schedule is the most common reason women switch away from liraglutide. Adherence at 12 months in real-world studies is lower than in trials, partly because of that daily burden.

Mounjaro: Once Weekly

Tirzepatide is injected once weekly, starting at 2.5 mg and increasing by 2.5 mg every four weeks up to 15 mg as tolerated. For women managing a busy life alongside a health condition, the once-weekly schedule tends to improve adherence. That practical difference may partially explain why real-world effectiveness tracks more closely to trial results for tirzepatide than for liraglutide.

Side Effects: What Women Report Most

Both drugs share the same core GI side-effect profile: nausea, vomiting, diarrhea, and constipation, all most common during dose escalation. A few differences are worth knowing.

Nausea and Gastrointestinal Symptoms

Nausea rates are somewhat higher with tirzepatide at the highest doses compared to liraglutide. In SURMOUNT-1, nausea occurred in about 31% of participants on tirzepatide 15 mg versus roughly 13% on placebo. In SCALE Obesity, nausea was reported in approximately 40% of liraglutide-treated participants at some point during the trial, though rates were often transient. Daily dosing with liraglutide means you encounter the drug's GI peak every day rather than once weekly, which some women find harder to tolerate.

Gallbladder Disease

Rapid weight loss from any GLP-1 may increase gallstone risk. Women already carry a higher baseline risk of gallstones than men, and that risk rises further during and after pregnancy, with oral contraceptive use, and at perimenopause. Ask your clinician about baseline gallbladder assessment if you have existing risk factors.

Pancreatitis and Thyroid C-Cell Risk

Both drugs carry a boxed warning for thyroid C-cell tumors (based on rodent data; FDA label). Neither drug is proven to cause medullary thyroid carcinoma in humans at this time, but both are contraindicated if you have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Women with a history of thyroid nodules should discuss this with their clinician before starting either agent.

Women's Health Conditions: PCOS, Perimenopause, and Beyond

PCOS (Reproductive Years)

PCOS affects approximately 8-13% of women of reproductive age globally and is driven largely by insulin resistance and compensatory hyperinsulinemia. Both liraglutide and tirzepatide improve insulin sensitivity and reduce fasting insulin. Small trials with liraglutide in women with PCOS showed improvements in menstrual regularity, androgen levels, and BMI. A 2023 systematic review in Fertility and Sterility found liraglutide significantly reduced testosterone and improved menstrual cycle regularity in PCOS, though study sizes were small.

No published randomized trial has specifically examined tirzepatide in women with PCOS as of early 2025. The extrapolation that tirzepatide's greater metabolic effect would translate to greater PCOS benefit is biologically plausible but not yet directly proven. Clinicians should note this evidence gap when counseling women with PCOS who are choosing between these two agents.

The framework below can help organize that conversation:

| Life Stage | Liraglutide | Tirzepatide | |---|---|---| | Reproductive / PCOS | Small RCT data for menstrual and androgen benefit | No PCOS-specific RCTs; extrapolated benefit | | Trying to Conceive | Must stop before conception | Must stop before conception | | Perimenopause | Off-label use; metabolic benefit plausible | SURMOUNT-1 included perimenopausal women; subgroup data limited | | Post-menopause | Longest real-world experience | Growing post-menopausal enrollment in trials |

Perimenopause and Post-Menopause

Weight gain during perimenopause follows a distinct pattern: central adiposity increases even without a change in caloric intake, driven by declining estrogen and changes in adipokine signaling. GLP-1 receptor agonists do not directly replace estrogen, but reducing central fat mass may improve insulin sensitivity and reduce cardiovascular risk, which escalates sharply after menopause.

The Menopause Society has not yet issued a specific practice guideline on GLP-1 use in menopause, but clinicians are increasingly prescribing both agents off-label for perimenopausal weight management. Women on menopausal hormone therapy (MHT) should know that estrogen can modestly increase GLP-1 receptor expression in animal models, though human interaction data between MHT and these drugs is sparse.

Thyroid Disease

Women are five to eight times more likely than men to develop thyroid disorders. Subclinical hypothyroidism is common in women over 40 and can blunt weight-loss response to any intervention. If your thyroid function is not optimized, the weight loss you see on either drug may be less than trial averages. Get your TSH checked before starting and after dose escalation if results are not responding as expected.

Pregnancy, Lactation, and Contraception: A Required Conversation

Both tirzepatide and liraglutide are contraindicated in pregnancy. This is not a soft recommendation. Animal studies with liraglutide showed embryofetal toxicity at doses below the human therapeutic exposure, and tirzepatide animal data similarly showed fetal harm. Human data are limited because pregnant women are excluded from trials, which means the true risk in human pregnancy is unknown but cannot be assumed to be zero.

Stopping Before Conception

The FDA-approved labeling for liraglutide recommends discontinuing the drug at least two months before a planned pregnancy. For tirzepatide, the current label advises stopping at least one month before planned conception, though some reproductive endocrinologists recommend a longer washout period of two to three months given the weekly dosing and longer pharmacodynamic effects.

If you are using either drug and not using reliable contraception, this needs to be addressed at your next visit. Women with PCOS who start GLP-1 therapy may experience restored ovulation before they expect it, increasing pregnancy risk even if cycles were previously irregular. This is a documented clinical scenario, not a theoretical one.

Lactation

Neither liraglutide nor tirzepatide is recommended during breastfeeding. Data on transfer into human breast milk are insufficient. Because both drugs are large peptide molecules, oral bioavailability in an infant would likely be low, but "likely low" is not the same as "proven safe." The conservative guidance from both manufacturers is to avoid use while breastfeeding.

For Women Trying to Conceive

Stop either drug before you begin trying. Use reliable contraception while you are on the drug. If GLP-1 therapy improved your PCOS-related anovulation and you are now ovulating regularly, talk with your clinician about whether you need hormonal contraception, barrier methods, or a combination, depending on your goals.

Who Is This Right For, and Who Should Look Elsewhere?

Women Who May Prefer Mounjaro (Tirzepatide)

• You have type 2 diabetes and your A1C needs substantial reduction alongside weight loss.
• You have tried liraglutide or semaglutide and lost less than 5% of body weight after 16 weeks.
• You can access the Eli Lilly savings program or have commercial insurance that covers it.
• A once-weekly injection fits your schedule better than a daily one.
• You need greater magnitude of weight loss for clinical reasons (severe sleep apnea, pre-surgical weight reduction, NASH).

Women Who May Prefer Liraglutide

• You are considering cost as the primary driver and generic liraglutide is available at your pharmacy for the diabetes indication.
• You have type 2 diabetes with relatively modest weight loss goals (5-8% body weight).
• You prefer a drug with a longer post-marketing safety record, particularly if you are close to reproductive age and may need to stop quickly.
• You have previously tried tirzepatide and experienced intolerable GI side effects; the different receptor profile of liraglutide may be better tolerated in some women.
• Your insurance covers liraglutide as a preferred tier drug and does not yet cover Zepbound.

Women Who Should Avoid Both

• Pregnancy or planning pregnancy within the next one to two months.
• Personal or family history of medullary thyroid carcinoma or MEN2.
• Active pancreatitis or a history of severe pancreatitis.
• Severe gastroparesis (both drugs further slow gastric emptying).

How to Switch From One to the Other

Switching from liraglutide to tirzepatide is common as tirzepatide access improves. There is no published protocol for this specific transition, but general clinical practice follows these steps:

1. Stop liraglutide on the day of the last injection.
2. Start tirzepatide 2.5 mg the following week, using the full standard escalation schedule.
3. Expect some nausea recurrence during the first two to four weeks, even if you tolerated liraglutide well. The GIP receptor component of tirzepatide produces a distinct GI signal.
4. Do not attempt to "skip" the starting dose because you were already on a GLP-1.

Switching in the opposite direction (tirzepatide to liraglutide) may be needed due to cost changes, insurance formulary shifts, or supply issues. Allow at least one week after the last tirzepatide dose before starting liraglutide, and begin liraglutide at 0.6 mg with the standard titration.

A 2023 clinical commentary in Obesity Medicine noted that switching between GLP-1 class agents generally does not require a washout period for safety reasons, though restarting the titration from the lowest dose is recommended for tolerability.

What the Evidence Does Not Yet Tell Us

Women have been historically under-represented in metabolic drug trials, and that gap applies here. Specifically:

• Sex-stratified weight loss data from SURPASS-2 and SURMOUNT-1 have not been fully published. Trial reports present pooled results.
• PCOS-specific trials with tirzepatide do not yet exist.
• Interaction with hormonal contraception has not been formally studied for tirzepatide. Liraglutide appears not to meaningfully affect ethinyl estradiol pharmacokinetics based on a small pharmacokinetic sub-study, but tirzepatide data are absent.
• Long-term cardiovascular outcome data for tirzepatide in women are pending. The SURPASS-CVOT trial is ongoing. Liraglutide has LEADER trial data (NEJM 2016) showing a 13% relative reduction in major adverse cardiovascular events in high-risk type 2 diabetes patients, giving it a cardiovascular outcomes advantage that tirzepatide cannot yet claim equally.

When your clinician says "both drugs are good options," part of what they mean is "we are still learning, and the data in women specifically are thin." That honesty should inform your decision, not paralyze it.

The Bottom Line on Efficacy, Cost, and Access

Tirzepatide produces greater weight loss and A1C reduction than liraglutide based on the best available trial evidence, though no direct head-to-head trial exists. SURPASS-2 demonstrated tirzepatide's superiority over semaglutide 1 mg, and SCALE Obesity places liraglutide's ceiling below what tirzepatide achieves in SURMOUNT-1.

Cost access has narrowed with generic liraglutide at the diabetes dose, but brand Saxenda at the obesity dose remains expensive. Mounjaro savings programs reduce cost for commercially insured patients, but Medicare and Medicaid coverage for obesity indications remains an active policy area.

The right drug is the one you can afford, tolerate, obtain consistently, and stop safely when your reproductive plans require it. At your next visit, ask your clinician to review your current life stage, your contraception plan if applicable, your insurance formulary, and your three-month weight loss response before assuming either drug is the permanent answer.